Two Re­pub­li­can sen­a­tors call on CMS to not re­strict cov­er­age to amy­loid-tar­get­ed Alzheimer's drugs

Re­pub­li­can Sen­a­tors Su­san Collins of Maine and Shel­ley Moore Capi­to of West Vir­ginia re­cent­ly sent a let­ter to CMS, urg­ing the agency to not move for­ward with its re­stric­tions on cov­er­ing amy­loid-tar­get­ed Alzheimer’s drugs ahead of an April 11 dead­line for a fi­nal na­tion­al cov­er­age de­ter­mi­na­tion.

The sen­a­tors joined a grow­ing cho­rus of more than 75 mem­bers of Con­gress and oth­ers in in­dus­try, like Bio­gen and BIO, who have in­sist­ed that a CMS de­ci­sion to re­strict these new and up­com­ing Alzheimer’s drugs to on­ly clin­i­cal tri­als would “in­ap­pro­pri­ate­ly threat­en pa­tient ac­cess to treat­ment,” and “thwart ad­vances” in Alzheimer’s R&D.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER